Amalgamated Bank lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 27.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 13,355 shares of the biopharmaceutical company's stock after acquiring an additional 2,877 shares during the period. Amalgamated Bank's holdings in Alnylam Pharmaceuticals were worth $2,181,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. IndexIQ Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 21.5% in the first quarter. IndexIQ Advisors LLC now owns 2,413 shares of the biopharmaceutical company's stock valued at $394,000 after buying an additional 427 shares in the last quarter. Cetera Advisor Networks LLC boosted its position in Alnylam Pharmaceuticals by 44.0% during the first quarter. Cetera Advisor Networks LLC now owns 4,299 shares of the biopharmaceutical company's stock worth $702,000 after purchasing an additional 1,313 shares during the period. Gateway Investment Advisers LLC boosted its position in Alnylam Pharmaceuticals by 474.4% during the first quarter. Gateway Investment Advisers LLC now owns 26,239 shares of the biopharmaceutical company's stock worth $4,285,000 after purchasing an additional 21,671 shares during the period. Swiss National Bank boosted its position in Alnylam Pharmaceuticals by 14.7% during the first quarter. Swiss National Bank now owns 518,010 shares of the biopharmaceutical company's stock worth $84,586,000 after purchasing an additional 66,300 shares during the period. Finally, Bank of Montreal Can boosted its position in Alnylam Pharmaceuticals by 86.8% during the first quarter. Bank of Montreal Can now owns 73,751 shares of the biopharmaceutical company's stock worth $12,433,000 after purchasing an additional 34,267 shares during the period. 93.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALNY. BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $192.00 to $200.00 and gave the stock a "market perform" rating in a research report on Friday, September 9th. Oppenheimer lifted their target price on Alnylam Pharmaceuticals from $170.00 to $256.00 and gave the stock an "outperform" rating in a report on Friday, September 9th. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the stock a "buy" rating in a report on Thursday, August 4th. Evercore ISI lifted their target price on Alnylam Pharmaceuticals to $252.00 in a report on Tuesday, August 9th. Finally, William Blair assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, June 7th. They set an "outperform" rating for the company. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $232.06.

Alnylam Pharmaceuticals Stock Down 1.0 %

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The business had revenue of $224.80 million for the quarter, compared to analyst estimates of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The firm's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.61) EPS. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.13 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,754 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $210.00, for a total transaction of $368,340.00. Following the sale, the executive vice president now directly owns 3,629 shares in the company, valued at $762,090. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 5,349 shares of company stock worth $1,033,073. Insiders own 1.40% of the company's stock.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Articles

• Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• 2 Semiconductor Stocks To Watch For Reversals

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.